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Abstract
Introduction: The objective of this study was to develop a process to maximize the safety and effectiveness
of disclosing Positron Emission Tomography (PET) amyloid imaging results to cognitively normal older adults
participating in Alzheimer’s disease secondary prevention studies such as the Anti-Amyloid Treatment in
Asymptomatic Alzheimer’s Disease (A4) Study.
Methods: Using a modified Delphi Method to develop consensus on best practices, we gathered and analyzed
data over three rounds from experts in two relevant fields: informed consent for genetic testing or human
amyloid imaging.
Results: Experts reached consensus on (1) text for a brochure that describes amyloid imaging to a person who is
considering whether to undergo such imaging in the context of a clinical trial, and (2) a process for amyloid PET
result disclosure within such trials. Recommendations included: During consent, potential participants should
complete an educational session, where they receive verbal and written information covering what is known and
unknown about amyloid imaging, including possible results and their meaning, implications of results for risk of
future cognitive decline, and information about Alzheimer’s and risk factors. Participants should be screened for
anxiety and depression to determine suitability to receive amyloid imaging information. The person conducting
the sessions should check comprehension and be skilled in communication and recognizing distress. Imaging
should occur on a separate day from consent, and disclosure on a separate day from imaging. Disclosure should
occur in person, with time for questions. At disclosure, investigators should assess mood and willingness to receive
results, and provide a written results report. Telephone follow-up within a few days should assess the impact of
disclosure, and periodic scheduled assessments of depression and anxiety, with additional monitoring and follow-up
for participants showing distress, should be performed.
Conclusions: We developed a document for use with potential study participants to describe the process of
amyloid imaging and the implications of amyloid imaging results; and a disclosure process with attention to
ongoing monitoring of both mood and safety to receive this information. This document and process will be
used in the A4 Study and can be adapted for other research settings.
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Introduction
Progress in Alzheimer’s disease (AD) biomarker discovery
has begun to transform how researchers and clinicians
define the disease. Researchers have proposed that AD
biomarkers are present prior to cognitive impairment
and associate with subsequent cognitive and functional
decline, supporting the concept of a ‘preclinical’ stage of
AD [1]. Among the candidate biomarkers to identify
this stage of AD, detection of fibrillar forms of amyloid-
beta using positron emission tomography (PET) imaging
has attracted considerable attention. Amyloid build up
may be among the first pathological changes in AD and
amyloid PET imaging may allow the identification of indi-
viduals at risk for progression to AD dementia and in
whom targeted interventions to prevent that disability can
be tested [2].
Among the studies needed to validate this stage of AD
are randomized and controlled clinical trials that test
whether intervening in cognitively normal persons who
have a biomarker delays the onset of, or alters the rate
of, cognitive decline. Such secondary prevention trials
will enroll persons meeting preclinical AD criteria to test
the efficacy of experimental compounds. These trials
serve an important public health goal, as they will con-
tribute to the National Alzheimer’s Project Act (NAPA)
goal to prevent AD by 2025 [3]. One example of a
secondary prevention trial is the Alzheimer’s Disease
Cooperative Study (ADCS) Anti-Amyloid Treatment in
Asymptomatic Alzheimer’s Study, or A4 Study [4].
The A4 Study will randomize 1,000 individuals with
elevated brain amyloid as seen on PET scan to receive
either a monoclonal antibody against the amyloid beta
protein or placebo. Compared to a secondary prevention
trial that includes a biomarker negative cohort blinded
and randomized to placebo, this approach reduces the
number of participants needed to enroll and avoids sub-
jecting individuals to study procedures that are unlikely
to benefit them [5]. It also allows researchers to study
how telling a person their biomarker status impacts their
cognition, cognitive symptoms, and well-being in the
context of participating in a clinical trial that tests an
intervention for biomarker positive persons.
As valuable as this approach may be, disclosing AD
biomarker results to cognitively normal older adults
does raise important clinical and ethical challenges. PET
amyloid imaging is Food and Drug Administration
(FDA) approved for the diagnostic work up of patients
with progressive cognitive impairment, and appropriate
use criteria recommend it only for persons with mild
cognitive impairment (MCI) or dementia with an unclear
or atypical cause. It is not recommended for cognitively
normal individuals in the clinical setting [6]. Disclosure
of AD biomarker results in a research context has been
discouraged due to lack of clinical utility and treatment
options and the prognostic uncertainty in this popula-
tion. Studies suggest that up to 30% of cognitively normal
older adults are amyloid positive, and at elevated risk
of developing AD symptoms, but their individual risk of
developing AD symptoms is not known [7]. A survey of
Alzheimer’s Disease Neuroimaging Initiative (ADNI)
researchers showed that both expert clinicians who sup-
ported and did not support disclosing amyloid imaging
results recognized a need for a process to disclose safely
and effectively and to study the impact of disclosure [8].
The goal of this study was to develop such a process
and to test the disclosure language in a sample of volun-
teers. The project in its entirety was a component of the
protocol development process for the A4 Study. We
sought to answer the following questions: What infor-
mation should an investigator disclose to AD prevention
trial participants pre- and post- amyloid imaging? What
are best practices for pre- and post- amyloid imaging
discussions? What should be measured to assess the im-
pact of learning this information in a clinical trial?
We utilized a modified Delphi method to develop ex-
pert consensus on best practices for amyloid results dis-
closure in AD prevention trials [9]. Expert consensus is
recognized as a viable method of providing a basis for
decision-making in situations where evidence from other
sources, such as randomized trials, is sparse or non-
existent [10].
Methods
Expert identification
The modified Delphi method we employed required an
expert panel that included researchers from each of two
relevant fields: informed consent for genetic testing and
AD biomarkers with a focus on amyloid imaging in
humans. To assure that individuals recruited for the ex-
pert panel were chosen using objective criteria, a version
of the knowledge resource nomination method based on
a strategic literature search was employed [9]. The study
required that experts be willing to participate in a three-
stage Delphi process.
The strategic literature search sought experts in in-
formed consent for genetic testing and AD biomarkers
with a focus on amyloid imaging in humans. The need
for experts in amyloid imaging is self-evident. We
sought experts in informed consent for genetic testing
because amyloid imaging in clinically normal individuals
is analogous to a genetic test in so far as it represents a
biological measure that is associated with the later risk
of a disease.
We defined an expert as an individual whose PubMed
citations showed a consistent pattern of publication in
either informed consent or amyloid imaging. We defined
a consistent pattern as at least three years of publica-
tions with attention to lead or senior author status and
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the quality of the publications based on journal type and
citations of the publication. Our target was to enroll 10
to 12 experts equally distributed between the two fields,
following suggestions in the literature that an expert
panel should include the minimally sufficient number of
respondents and that a panel of 10 to 15 experts is
adequate for relatively homogenous groups [11].
To identify experts in the field of amyloid imaging
and AD biomarkers, we searched Medline for recent
and relevant publications, performing searches for
keywords: ‘amyloid imaging’ , ‘Alzheimer Disease (sub-
heading ‘ri (Radionuclide Imaging)’)’ , and combina-
tions of keywords ‘Alzheimer Disease’ AND ‘amyloid
imaging’. All searches were limited to publications
written in English from the year 2000 to 2012.
For the search to find experts on informed consent
and genetic testing, we conducted Medline searches
for recent and relevant publications, using keywords
‘Informed Consent’ , ‘Genetic Testing’ , and ‘Ethics’ and
combinations of these keywords. All searches were
limited to publications written in English from the year
2000 to 2012.
We reviewed the search results and identified potential
expert participants based on the criteria described above.
We produced an initial list of 20 individuals with
consistent publication records in amyloid imaging and
20 individuals with consistent publication records in
informed consent. We then randomly arranged the list
of experts and serially recruited them in batches until
we achieved our desired numbers.
We solicited expert participation via email that de-
scribed the three rounds of Delphi review and then sent
letters to those who did not respond or for whom email
addresses were not available. Follow up letters were
sent two weeks after the initial solicitation. After three
attempted contacts, it was assumed that an individual
did not wish to participate.
Delphi round 1
All experts who agreed to participate were sent a Power-
Point slide set describing the basics of amyloid imaging
and its role in trials such as the A4 Study. Experts then
participated in one-on-one semi-structured telephone
interviews with a trained research assistant (copies of
the slide set and interview script are available upon
request). The research assistant confirmed at the begin-
ning of the interview that the expert had reviewed the
PowerPoint slides. If not, the interview was rescheduled.
The interviewer answered any questions about the slides.
Experts were then asked questions to elicit their ideas
about the process and topics to be covered during three
different phases of the A4 study: before consent, after
consent but prior to amyloid imaging, and after amyloid
imaging. The goal of this step was to identify potential
disclosure topics and an outline of the disclosure process.
We transcribed interviews and reviewed responses to
identify and remove duplicate responses, and standardize
language. We organized responses into the following
domains: topics, methods/steps, assessments, and mate-
rials for education and assessment. Each domain was again
separated into three phases: before consent, after consent
and after imaging.
Delphi round 2
We sent the revised response list to experts via an online
survey. For each item, experts used a three point scale
(should be included, unsure, should not be included) to
rate the necessity/appropriateness of including it. We
also provided space for experts to comment on the
reasons for their ratings.
We compiled the responses and categorized items into
three levels of support: consensus to include (≥80%
support), mixed support (79% to 50% support) and not
supported (<50% support). Mixed support items were
construed as having been supported if the majority of
remaining votes were ‘unsure’ rather than ‘do not
include’.
We used the list of items with consensus support to
draft text for an Amyloid Imaging Disclosure Process
Instructional Manual (hereafter called ‘the instructional
manual’) and to create an Amyloid Imaging Disclosure
Process brochure (hereafter called ‘the brochure’). The
instructional manual is intended for investigators and
clinicians, and describes each topic and creates a tem-
plate for the process of amyloid result disclosure in the
context of the A4 Study. The brochure describes amyl-
oid imaging and is intended for education of a person
who is considering whether to undergo it in the con-
text of a clinical trial. We subsequently revised and
refined the text in both drafts in collaboration with A4
investigators.
Delphi round 3
We sent the draft brochure text to experts via an online
survey. Experts rated each section (and the overall docu-
ment) for clarity on a 1 to 5 scale (‘not at all clear’ to
‘extremely clear’). We provided space for experts to
comment on the reasons for their ratings or provide
suggestions for additional topics, changes and deletions.
We used expert comments to revise the brochure, with
particular attention to any sections with mean clarity
ratings less than 4.
Examine readability with cognitively normal older adults
Based on the results of Round 3, we tested a template
version of the brochure that was not specific to the A4
study with a group of five cognitively normal older
adults. Participants were a convenience sample recruited
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from the University of Pennsylvania Alzheimer’s Dis-
ease Center’s normal control cohort, who had given
permission to be contacted for studies such as this
one. We selected these persons because they would
be the kind of person recruited for an AD secondary
prevention trial. We asked participants to review the
brochure prior to a face-to-face meeting with a trained
research assistant. The research assistant assessed un-
derstanding using standardized measures developed in
the decisional capacity literature that asked persons to
‘say back’ the meaning of a section, and reviewed
sections with poor understanding for suggestions on
improving clarity.
Human subjects’ protections
The Delphi study did not require Institutional Review
Board (IRB) approval because it was a project designed
to develop educational materials and, thus, did not fall
under the category of activities requiring review under
the Common Rule. The interview with the cognitively
normal older adults was approved by the University of
Pennsylvania IRB and all participants gave informed
consent to participate.
Results
Expert identification
A total of 21 individuals were contacted (10 informed
consent experts, 11 amyloid imaging experts); 14 agreed
to participate, 1 refused, and 6 did not respond. Twelve
experts completed a round 1 interview (six amyloid and
six informed consent); two who had agreed to partici-
pate could not be reached for interview. Individuals who
did not complete interviews were not included in the re-
mainder of the study. Ten experts completed the round
2 survey (five amyloid and five informed consent), with
two experts not responding, and nine experts completed
the round 3 survey (five amyloid and four informed
consent).
Members of the expert panel came from a variety
of disciplines and organizations in the U.S. and Europe.
Experts from positions in academia, clinical practice,
industry and government were included. The amyloid
imaging experts included primarily clinical neurolo-
gists, as well as radiologists, psychiatrists and neu-
roscientists. The informed consent experts included
individuals with backgrounds in philosophy, clinical
psychology, law, genetic risk assessment and disclos-
ure, and research and medical ethics. The expert
panel and our investigative team included members
of the Society of Nuclear Medicine and Molecular
Imaging and the Alzheimer’s Association Amyloid Imaging
Task Force who produced the Appropriate Use Criteria
for Amyloid PET imaging [6].
The Delphi process
Interviews in Round 1 produced 207 unique suggestions
regarding the disclosure of amyloid results in the context
of an AD prevention trial: 93 items related to topics to
discuss, 55 to participant assessments, 39 to disclosure
process methods and 20 to materials to utilize.
Responses on the Round 2 surveys indicated con-
sensus to retain 70 items related to topics to discuss, 25
items related to participant assessments, 29 items
related to disclosure process methods and 8 items re-
lated to materials to utilize. We removed items that are
standard practice in clinical trials (such as obtaining
informed consent) and then used the survey responses
to develop the Amyloid Imaging Disclosure Process
brochure and instructional manual. The manual is dis-
played in Table 1.
Round 3 survey responses showed high clarity ratings
for brochure sections. Mean section clarity ratings
ranged from 3.67 to 4.5, with only two sections receiving
mean clarity ratings lower than 4. We revised brochure
sections based on clarity ratings and specific expert
comments. In particular, we simplified language and
added text explaining that a person could have an ele-
vated amyloid scan and never develop AD dementia.
Test for readability with cognitively normal older adults
A convenience sample of five cognitively normal adults
(all who were approached agreed to participate) com-
pleted in-person interviews using the template brochure.
All participants were non-Latino whites and 80% were
women. Average age was 89 ± 3.8 years (range 82 to 91).
Participants averaged 14.4 ± 2.6 years of education (range
12 to 18).Testing of the generalized version of the bro-
chure, without specific reference to A4, showed that
older adults found the brochure clear and comprehen-
sible, and were able to summarize key points after
reviewing the document. We made minor changes based
on their recommendations, including removing redun-
dant wording and adding information about the progres-
sion of AD symptoms over time. Topics and key points
from a template version of the brochure which can be
adapted for any secondary prevention trial are displayed
in Table 2.
Discussion
Disclosing AD biomarker results to cognitively normal
older adults in a research setting raises clinical and eth-
ical challenges and has been discouraged due to prog-
nostic uncertainty and lack of clinical utility. However,
the design of secondary prevention trials that will en-
roll only cognitively normal individuals with Alzheimer’s
biomarkers necessitates disclosure, and so a process to
safely and effectively disclose such results is urgently
needed [8,15,16]. Creating a safe and effective disclosure
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fulfils the principles of respect for individuals’ autonomy
(competent participants should make a fully informed
and voluntary decision), and non-maleficence, (they
should not be harmed by the information).
To fill this gap in knowledge, we utilized a modified
Delphi procedure to develop expert consensus on topics to
be discussed and best practices for amyloid imaging result
disclosure to cognitively normal research participants. The
Table 1 Amyloid imaging disclosure process instructional manual
Best practice Details
Step 0: Prior to in-person screening
Send Amyloid Imaging Disclosure Process brochure prior to consent. Brochure content descriptions are provided in Table 2.
Step 1A: Education and informed consent
Assess knowledge of study and role of amyloid imaging in study. Use this information to structure review of the brochure.
Assess motivation for joining study. Example questions:
Tell me what you know about an amyloid PET scan?
Why are you interested in having an amyloid PET scan?
Why are you interested in joining the study?
Conduct educational session. Cover brochure contents and tailor based on participant’s prior
knowledge.
Study staff should be skilled in communication.
Explain meaning of elevated amyloid on PET scan, clarify that
this does not necessarily mean that an individual will develop
symptoms of Alzheimer’s disease
Assess understanding of brochure. Use “teach back” method: “Can you tell me in your own words
what we just talked about?”
Focus on understanding of amyloid imaging and its role in study.
Step 1B: Screening assessments
Screen for anxiety and depression (for example: State-Trait Anxiety
Inventory (STAI) [12] and Geriatric Depression Scale (GDS) [13])
Decisions on eligibility will be study-specific and involve
investigator’s clinical judgment.
Step 2: Amyloid PET scan
Participant undergoes amyloid PET scan. Conduct imaging on a separate day from consent.
Do not disclose results on the day of imaging.
Step 3A: Amyloid status disclosure - pre-disclosure
Assess mood. Investigator/study staff should be skilled in communication and
recognition of distress.
(For example: STAI and GDS)
Assess recent life stress.
Assess willingness to receive result. If concerns arise, discuss possibility of delaying disclosure.
Step 3B: Amyloid status disclosure
Disclose amyloid status using language from the brochure. Disclose in-person, with time for questions.
Give participant option of having family member or friend present.
Provide a written summary.
Assess understanding of amyloid status result. Example questions:
What does that mean to you?
Do you have any questions about your result?
Step 4: Post-disclosure follow-up
Conduct follow-up phone call one to three days post-disclosure. Assess well-being, distress, and impact of disclosure. (for example:
Impact of Event Scale (IES) [14])
Answer questions.
Create appropriate follow-up plan based on participant’s responses.
Step 5: Follow-up over study course
Assess anxiety, depression, impact of disclosure. Study protocol should specify frequency of assessments and plans
for additional monitoring if distress is observed.
(for example: STAI, GDS, IES)
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Table 2 Amyloid imaging disclosure process brochure template
Brochure topic Key points
What is the (insert name of secondary prevention trial
(for example: A4 study)) Trial?
● This should be study specific and include basic enrollment criteria,
objective, and study design
Why is this (insert name/description of intervention)
being tested?
● This should be study specific and include basic explanation of the
intervention’s mechanism and safety profile
What will happen if I enroll in the (insert name of
secondary prevention study) Trial?
● This should be study specific and include information about the
screening and enrollment process and study procedures
What is Alzheimer’s disease? ● Alzheimer’s disease is a brain disease.
● It is the most common cause of dementia.
● Common symptoms of dementia caused by Alzheimer’s disease are
problems with memory and thinking that impair a person’s ability to
do their usual and everyday activities.
● As persons with Alzheimer’s disease develop symptoms, the first to
appear are memory and thinking problems that are bothersome but do
not interfere with daily activities. Over time, usually several years, as these
problems worsen, the person develops dementia.
What is amyloid? ● Amyloid is a protein in the brain
● In Alzheimer’s disease, amyloid builds up and brain function gets
worse
● Amyloid can sometimes be detected years before a person has
noticeable memory problems.
How do we know whether someone has brain amyloid? ● An amyloid PET scan measures brain amyloid.
What does having a brain amyloid scan involve? ● An injection of a radioactive drug.
● The scan measures the level of amyloid in your brain.
What does an elevated level of brain amyloid mean? ● An ‘elevated amyloid’ result:
- means that amyloid plaques are present in your brain.
- does not mean you now have Alzheimer’s disease dementia or that you
will ever get Alzheimer’s disease dementia.
- means you may be eligible to join Alzheimer’s prevention trials that will
test anti-amyloid therapies.
● Recent studies suggest that elevated levels of amyloid may increase your
risk of developing Alzheimer’s disease dementia in your lifetime.
Is an elevated level of amyloid like other medical risks? ● The relationship between elevated amyloid and Alzheimer’s disease
dementia is similar to the relationship between high cholesterol and
heart disease.
● Many factors protect a person from developing memory or thinking
problems even if they have elevated levels of amyloid.
● Good general health and a healthy lifestyle are known to lower the risk
of Alzheimer’s disease dementia.
What does a not elevated level of brain amyloid mean? ● A ‘not elevated’ amyloid result:
- means that it is unlikely you have amyloid plaques in your brain at this
time.
● A person who has a ‘not elevated’ amyloid level could develop:
- an ‘elevated’ level in the future.
- Alzheimer’s disease dementia in the future.
Why is a brain amyloid scan necessary to participate in
the (insert name of secondary prevention study) Trial?
● The trial will test whether an amyloid lowering drug given to people
with elevated amyloid will lower the amount of brain amyloid and also
prevent or slow declines in memory.
(This text can be edited to fit the specific secondary prevention trial’s goals
and intervention)
● The brain amyloid scan will indicate whether a person has elevated
amyloid and is then eligible to participate in the trial.
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best practices include pre- and post-imaging recommenda-
tions and are compiled in the ‘Amyloid Imaging Disclosure
Process Instructional Manual’. Text covering the topics to
be addressed is included in the ‘Amyloid Imaging Disclosure
Process Brochure’. Versions of both documents are being
utilized in the A4 Study and can be adapted for use in other
prevention trials.
The disclosure process includes a detailed pre-consent
educational session focused on informing participants of
what is known and unknown about amyloid imaging,
detailing possible imaging results and their implications,
and providing context in the form of basic information
about Alzheimer’s disease and its risk factors. The process
also includes careful participant screening, mood monitor-
ing, and a protocol for monitoring and addressing distress.
Mood monitoring should include assessment of depression,
anxiety, and the impact of the disclosure event using stand-
ard, validated instruments. Strategies to assess comprehen-
sion, such as the ‘teach-back’ method, are addressed, as
well as required research staff skills, including clear
communication and ability to recognize and respond to
participant distress.
This amyloid imaging disclosure process was designed
with the goal of minimizing the risks of disclosure. These
risks, which have been described elsewhere [17-20], in-
clude potential psychological reactions such as anxiety
and depression, misunderstanding of the result and its
implications – in particular, believing that an elevated
amyloid scan indicates a clinical diagnosis of Alzheimer’s,
stigma in interpersonal relationships, discrimination in
realms such as insurance and employment, and effects on
cognitive performance due to stereotype threat.
The process we developed is similar in many respects
to a proposed process for disclosing PET amyloid imaging
to persons with mild cognitive impairment [21-23]. Those
investigators developed disclosure materials through con-
sultation with a panel of experts, piloted the materials in
mock disclosures to MCI patients and their family mem-
bers, and conducted follow-up focus groups with MCI
patients and family members for additional feedback. They
found that patients and family members generally under-
stood the imaging results and were satisfied with the
disclosure process. Specific recommendations included
conducting pre-test counseling, using clear graphics,
reviewing patient’s scan images during the disclosure
session, providing take-home materials with follow-up
information, conducting phone follow-up after disclosure,
and communicating with primary care providers to facili-
tate treatment planning [21-23]. The A4 study does not
show participants’ scan images or provide specific quanti-
tative results from the amyloid imaging. Reviewing the
PET scans during disclosure was suggested in Round One
interviews, but we did not find consensus to do so in later
Delphi rounds. Further research is needed to determine
participants’ desire to view their images, how to present
visual or quantitative information from the scans, and
what the impact of this additional information is.
The development of this disclosure process and docu-
ments is only a first step. Research is needed to analyze
the actual safety and effectiveness of this process, includ-
ing how well it works (for participants and trial staff ), and
what are the effects (psychological, social, legal, cognitive,
behavioral) of amyloid imaging result disclosure on
cognitively normal research participants who have and
do not have evidence of elevated amyloid accumulation.
The Risk Evaluation and Education for Alzheimer’s
Disease (REVEAL) studies have shown that information
about genetic risk for Alzheimer’s can be safely and
effectively disclosed to research participants with minimal
harm [24-27]. The process developed here is quite similar
to REVEAL Study methods, although key differences
between genetic risk and biomarker positivity may lead
to differences in participant reactions. Data on the
impact of disclosure will be collected through a variety
of measures – many adapted from the REVEAL Study –
within the A4 study, as well as through an add-on study
involving qualitative interviews with A4 participants
and individuals who screen out of A4 due to not having
elevated amyloid. These interviews will address the im-
pact of receiving amyloid imaging results, including be-
haviors adopted since learning amyloid imaging results,
sense of self, experiences of sharing the results with
others, and experiences of discrimination or stigma.
The data from A4 and the qualitative interviews will be
analyzed to validate and refine the disclosure process.
Our study is limited by drop out or non-participation
among five experts over the course of the study, who,
it is possible, had views markedly different from the
experts who did respond and so would have shaped our
results in a different manner. Second, while we did test
the materials in a group of cognitively normal older
adults, our sample was relatively well-educated and not
ethnically diverse. Evidence to inform whether the mate-
rials achieve the goal of safely disclosing results to older
adults awaits the actual implementation in the A4 Study,
a process that is ongoing and results are expected by the
close of 2015. Further study is necessary to determine
whether learning this information under circumstances
outside of a clinical trial testing a potentially beneficial
intervention would be safe. Those results, as well as
additional data on the clinical significance of amyloid
imaging in cognitively normal older adults, will likely
require further revisions of this process.
Conclusions
We utilized a modified Delphi Method to develop a
document for use with potential AD secondary prevention
study participants to describe the process of amyloid
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imaging and the implications of amyloid imaging results;
and a disclosure process with attention to ongoing moni-
toring of both mood and safety to receive this informa-
tion. This document and process will be used in the A4
Study and can be adapted for other research settings.
Evidence to inform whether the materials achieve the goal
of safely disclosing results to older adults awaits actual
implementation of the process in A4 and other studies.
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